CF Together’s Post

🔔 Latest publication alert! A review of 25 years of decision-making by the National Institute for Health and Care Excellence (NICE). Our comprehensive review of all medicines appraised by NICE since 1999 reveals key trends and insights into patient access to therapies. Key findings include: 📉 42% of medicines were recommended - this has decreased over time from the initial 4 year period at 95% to the most recent 4 year period at 28%. 📊 31% received optimised recommendations - this might be impacting patient access as a recent study highlighted that optimised recommendations may restrict patient populations who can access the medicine. 📝 We also observed an increase in manufacturers not submitting to NICE which may be related to difficulties in demonstrating value of combination therapies in the current NICE framework as well as limited options for indication-based pricing. Dive into the full review here: https://lnkd.in/eCiM4JHa Sreeram Ramagopalan | Natalie Tikhonovsky | Xin Zhang

Yesterday, Sen. Bernie Sanders (I-Vt.), announced he is launching an investigation into the pricing of Novo Nordisk's GLP-1 based medicines. Sen. Sander's letter stands on a shaky foundation, built on cherry-picked data and ignores evidence that the medicines are priced in a cost-effective manner. Efforts to address affordability should be based on validated evidence that takes the entire innovation ecosystem into account. Congress should also prioritize passage of The Treat and Reduce Obesity Act (TROA), bipartisan, bicameral legislation that would expand coverage of health care specialists and weight management treatments for Medicare patients. https://lnkd.in/eUfZeVt7

#Webinar alert from The Evidence Base® EU HTA – Achieving broad access fast! What will it take for innovative medicines to succeed? December 3, 2024; 4:30PM CET; 3:30PM GMT; 10:30PM ET Join our discussion on recent national reforms and essential policies to accelerate patient access to groundbreaking medicines. Moderator, Herbert Altmann (Cencora), will be joined by Iga Lipska MD PhD MPH (Health Policy Institute Poland), Francois Meyer and Oriol Solà-Morales (HiTT - Health Innovation Technology Transfer). #heor #healtheconomics #outcomesresearch #healthoutcomes #rwe #rwd #realworldevidence #realworlddata #marketaccess #pharma #biopharma #medicalaffairs #regulation #regulatoryaffairs #hta #healthtechnologyassessment #healthdata #healthpolicy #JCA #jointclinicalassessment

Let's discuss how to generate a Patient Centered Outcomes Research to enrich your value proposition - get the patient perspectives with robust methodologies

Polypharmacy, or the use of multiple medications by an individual (typically seen in population aged 60 and above) , can pose significant risks to the health, quality of life and overall well-being. While medications are often necessary to manage various health conditions, the simultaneous use of multiple drugs can increase the likelihood of adverse drug reactions, drug interactions, medication errors, and decreased adherence to treatment plans. It can also lead to confusion, falls, hospitalizations, and a decrease in overall quality of life. Managing polypharmacy requires careful monitoring, medication review, and coordination among healthcare providers to optimize therapy and minimize risks. Kudos to the impactful work done by iSimpathy project. Through informative guides and engaging animations, healthcare professionals are empowered with resources on treatment cost-effectiveness and the pharmacist's vital role in medicines reviews. Patient-centric materials including leaflets and videos also ensure informed decision-making and preparation. Check out bayartis GmbH to learn how we plan to tackle the challenges of Polypharmacy by providing simple tools to patients and caregivers for better awareness in a easy to understand simple language. #Polypharmacy #HealthcareInnovation #PatientEmpowerment #iSimpathyProject #Bayartis

🔭 From 12 January 2025, the new EU Health Technology Assessment (#HTA) procedure will support faster #access to innovative health technologies for patients across #Europe, by setting up a “one-stop-shop” for Joint Clinical Assessment (JCA), reducing the burdens of the current fragmented approach to HTA in the EU. While medicinal products for #RareDiseases will generally not be subject to the new requirements before 13 January 2028, Advanced Therapy Medicinal Products (#ATMPs) and Orphan Medicinal Products (#OMPs) for rare cancers will already be subject to the new procedure starting next year.   🤝 EUCOPE is supporting the efforts to speed up access to innovative medicinal products for those people living with a rare disease who currently do not have a treatment option. As a member of the HTA Stakeholder Network we aim to support the technical discussions on the implementation of the new procedure, highlighting the need for:   👉 Methodologies that account for the specificities of OMP development, which often relies on alternative methods of evidence generation and interpretation, such as single-arm trials, registry data, Real-World Evidence (#RWE) and Indirect Treatment Comparison. To ensure that the new procedure supports faster access to innovative medicinal products for rare disease patients, it is crucial that the JCA reports provide the necessary information needed for national decision-making.   👉 Involvement of rare disease patient and clinical experts in #EU HTA, including in the Joint Scientific Consultations (JSC) to support the trial design and evidence generation that meets the needs of people living with a rare disease and is tailored to the JCA requirements, and in the JCA, to provide the unique perspectives only these experts can provide. 📑 With the multi-stakeholder OD Expert Group, EUCOPE has developed proposals for a EU HTA fit for rare diseases, that is capable of addressing the key challenges linked to #development and assessment of medicinal products for rare and ultra-rare conditions. 🔗 Learn more here: https://lnkd.in/dZP6AENE   #RareDiseaseWeek #RDD2024 #EUHTA #Innovation

Medichem proudly attended the Annual Conference of Medicines for Europe in Dublin, celebrating 30 years of advancing #equitable #access to off-patent medicines. Off-patent medicines, crucial to Europe's healthcare, supply 70% of essential treatments, including those for cancer, autoimmune diseases, diabetes, and cardiovascular conditions. Generic medicines comprise over 90% of the EU's critical medicines list, reinforcing our industry's vital role in a resilient European health system. Challenges and opportunities in our sector:  ▶️ Enhancing the value proposition of off-patent medicines for cost-effective treatment options. ▶️ Promoting the use of #genericmedicines and overcoming barriers to their adoption. ▶️ Ensuring the future #supplychain #security of critical medicines through #robust European regulation and policy. ▶️ Innovating existing treatments with value-added medicines to support #sustainable health systems. ▶️ Combining environmental sustainability with improved access to medicines Elisabeth Stampa, President of Medicines for Europe and Board Member of Medichem, called for new EU leadership to prioritize a Critical Medicines Act and adopt new pharmaceutical legislation swiftly. Medichem is proud to support this vital industry and remains dedicated to creating a more accessible future for Europe. https://lnkd.in/dFkwpRGu

Medicines Development for Global Health is pleased to report that the ongoing Phase 2 trial in scabies, MDGH-MOX-2002, has now enrolled over 50 patients from sites in the United States, Honduras, the Dominican Republic and El Salvador. This study is investigating the potential for moxidectin as a single-dose oral treatment for human scabies. Atticus Medical is supporting this study which is sponsored by Medicines Development for Global Health. More than 200 million people around the world are infested with the scabies mite at any given time across low-, middle- and high-income countries. A single-dose treatment that removes the need for follow-up visits would be a significant improvement to the current standards of care, which usually requires repeat doses to be completely effective. Read more about this program at https://lnkd.in/gr5Gg-nm Study MDGH-MOX-2002; NCT05875441. #moxidectin #beatNTDs #scabies #GlobalHealth #clinicalresearch

Article ✍🏻 | Integrate the patient perspective into your value strategy   The landscape of healthcare is constantly evolving. But today it’s all obvious that incorporating the patient’s perspective into value strategies has become essential.   Health agencies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) are willing to approve treatments that the patient really needs. Healthcare agencies and, more generally, healthcare systems around the world want to provide care that is not only effective, but also patient centered.   📰 This article explores practical ways of integrating the patient perspective into value strategy, to ensure that future patient healthcare solutions are not only clinically effective, but also fully meet patients’ deepest needs.   Dive into our latest article: "How to integrate the patient perspective into your value strategy?" 🚀 Read now 👉 https://lnkd.in/efMVbSt6 #patientperspective #QoL #valuestrategy #patients